T1	Participants 0 98	Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis
T2	Participants 161 315	To assess patient-reported outcomes (PROs) for tofacitinib, an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA), in a 6-month, phase III,
T3	Participants 353 509	Patients ages ≥18 years with active RA with an inadequate response to ≥1 tumor necrosis factor inhibitor (TNFi) and receiving stable background methotrexate
